XKRX
008930
Market cap2.77bUSD
Oct 08, Last price
54,900.00KRW
1D
-5.51%
1Q
64.37%
Jan 2017
-10.15%
Name
Hanmi Science Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hanmi Science Co., Ltd. operates through its subsidiaries to produce and distribute pharmaceutical products both within South Korea and internationally. The company's research and development initiatives primarily target treatments for diabetes and various types of cancer. Its extensive product line further includes active pharmaceutical ingredients, general therapeutic drugs, nutritional supplements, and a variety of health-related goods and services. Additionally, it manages an online pharmacy platform and provides automated systems for pharmaceutical administration. The firm, which was initially established as Hanmi Holdings Co., Ltd. in 1973, adopted its current name, Hanmi Science Co., Ltd., in March 2012, and its corporate headquarters are situated in Seoul, South Korea.
Key people
Vice Chairman · since 2025
Gyeong Suk Kim
Vice President · since 2024
Won Hwa Jung
Assistant Managing Director · since 2024
Dae Su Jung
Assistant Managing Director · since 2023
Jun Seop Shin
Assistant Managing Director · since 2023
Seong Hun Kim
Managing Director · since 2025
Vice Chairman · since 2025
Vice President, Director · since 2025
Chairman, Chief Executive Officer · since 2025
Other Non-Executive Director · since 2024
Dong Guk Shin
Other Non-Executive Director · since 2024
Non-Executive Independent Director · since 2025
Yeong Hun Kim
Non-Executive Independent Director · since 2025
Yong Sam Shin
Non-Executive Independent Director · since 2025
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||